Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján
The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
LifeTime Media Kft
2017
|
| Sorozat: | IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE
70 No. 11-12 |
| doi: | 10.18071/isz.70.0381 |
| mtmt: | 3305055 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/12621 |
| Tartalmi kivonat: | The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 381-387 |
| ISSN: | 0019-1442 |